Ocera Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of clinical candidates for the treatment of gastrointestinal and liver diseases announced today that it has raised a $12 million Series B financing. The financing
will be used to continue clinical development of the company's first product,
AST-120. A pivotal Phase III clinical trial for AST-120 was initiated in the first
quarter of 2006 for the treatment of fistulizing Crohn's disease. The Series B
round was led by new investor, Sofinnova Ventures. Previous investors, Domain
Associates, LLC and Thomas, McNerney & Partners, LLC also participated in
this financing.
BioSpace
Simplifying Global Compliance
Recommended Products
EU MDR Compliance: A Checklist for Meeting Manufacturing, Safety and Performance Requirements
The FDAnews report EU MDR Compliance can help. Our editors have combed through the regulations, picking out the most minute compliance points and building them into a checklist of 200+ requirements you can use to confirm that you are satisfying all the EU mandates for device manufacturing.
Accelerating Generic Drug Development: The FDA’s New Plan for Increasing Generic Competition
Accelerating Generic Drug Development explains the FDA’s new policy and shows how to navigate the new pathway to approval.
Editor's Picks
J&J Enters Robotic Surgery Market
The companies entered into a cooperative agreement in May 2018 to combine J&J’s NeuWave system with the Monarch platform.
CDER’s Regulatory Modernization Will Peak in 2019, Woodcock Says
The center expects to have its proposed reorganization approved by HHS towards the end of FY 2019.
FDAnews Drug Daily Bulletin
OCERA THERAPEUTICS, INC. RAISES $12 MILLION SERIES B FINANCING
July 11, 2006
